Recruiting Psoriasis Studies in Birmingham
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis...
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study tr...
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-ter...
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis...
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE). The initial PK ...
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderat...
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis....
About Psoriasis Clinical Trials in Birmingham
Psoriasis is a chronic autoimmune skin condition affecting over 8 million Americans, causing cells to build up rapidly on the surface and forming red, scaly patches that can be itchy and painful. Plaque psoriasis accounts for about 80-90% of cases. While current treatments include topical therapies, phototherapy, and biologics like TNF inhibitors (adalimumab, etanercept) and IL-17/IL-23 inhibitors (secukinumab, guselkumab), clinical trials are testing next-generation oral treatments, TYK2 inhibitors, and combination approaches that may offer longer remission periods with fewer side effects. Patients with moderate-to-severe psoriasis who have not responded adequately to existing therapies are often sought for clinical trial enrollment.
There are currently 7 psoriasis clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 7,306 participants. Research is being sponsored by Bristol-Myers Squibb, Takeda, Alumis Inc and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Psoriasis Clinical Trials in Birmingham — FAQ
Are there psoriasis clinical trials in Birmingham?
Yes, there are 7 psoriasis clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Birmingham?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.
Are clinical trials in Birmingham free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.
What psoriasis treatments are being tested?
The 7 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for psoriasis.
Data updated March 2, 2026 from ClinicalTrials.gov